Phase 3 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who test positive for a specific genetic marker called HLA-A*02:01
• People who have been diagnosed with Stage IV melanoma, or Stage III melanoma that cannot be removed by surgery, confirmed through a tissue biopsy
• People who can provide a stored or fresh tumor tissue sample that meets the trial's quality requirements
• People whose cancer can be measured using standard imaging scans
• People who have had their tumor tested to find out whether a specific gene change called BRAF V600 mutation is present or absent
• People who are in good enough general health to carry out daily activities with little to no limitation (rated 0 or 1 on a standard medical scale)
• People of childbearing potential who are sexually active with a partner who has not been sterilised must agree to use highly effective contraception from the time of screening until 5 months after the last dose of the trial treatment

Who may not be able to join:

• People who have had another type of cancer (other than the melanoma being studied in this trial)
• People who have brain or spinal cord metastases that are untreated, currently active, or causing symptoms, or who have cancer that has spread to the lining of the brain or spinal cord
• People who have had a serious allergic reaction to any of the trial drugs (IMC-F106C, nivolumab, or relatlimab) or their ingredients
• People who have significant lung disease or seriously reduced lung function
• People who have significant heart disease or seriously reduced heart function
• People who have an active autoimmune disease that requires medication to suppress the immune system
• People who have any other poorly controlled medical condition that, in the judgement of the trial doctors, could affect safety, the ability to follow trial procedures, or the reliability of results
• People who have already received systemic (whole-body) drug treatment for melanoma that cannot be removed by surgery or has spread to other parts of the body
• People who have previously had a life-threatening side effect related to certain immunotherapy drugs (anti-PD-(L)1 or anti-LAG-3 treatments)

Important: Always verify eligibility with the trial site directly before applying.